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Introduction
Active surveillance (AS) is increasingly being used as an alternative to immediate radical 2 intervention for men with localised prostate cancer, at low risk of progressing to life 3 threatening disease (1) (2) (3) . As radical treatment comes with a risk of harm (4) , there is strong 4 motivation to intervene in only those men with a high risk of disease progression. 5 Circulating prostate specific antigen (PSA) has been used as a biochemical measure of 6 prostate cancer for many years. AS commonly includes regular measurement of PSA, with 7 increasing values used as a trigger for review. If signs of disease progression are found on 8 clinical review, there is the opportunity for radical intervention before the opportunity for 9 cure has passed. 10 Dynamic measures of PSA, such as PSA doubling time and PSA velocity are used by several 11 AS studies to alert clinicians to rapidly rising PSA (5) . Furthermore, PSA levels increase 12 naturally with age, and methods are being developed to indicate when increases in PSA are 13 beyond normal age-related (6) (7) (8) (9) . However, there is currently no evidence on whether there 14 is common PSA change in men with localised prostate cancer in different populations. 15 Although AS studies are beginning worldwide, the larger, more mature cohorts are based in 16 Europe and North America (10) . Differences in the effect of PSA screening have been 17 suggested between these populations (11, 12) , although there are several flaws with this 18 interpretation (13) . Nevertheless, the American Medical Association recommends annual 19 screening after age 55 in the US (14) , while no such recommendations exist in Europe. 20 This could lead to different populations of men with prostate cancer in the US (e.g. detected 21 at an earlier stage), who then may or may not have similar PSA kinetics to their European 22 counterparts. Thus it is unclear whether longitudinal PSA changes may differ in men on AS. 23 
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Monitoring protocols and triggers for clinical review are being devised to suit all men on AS 24 without requiring recalibration to each new population. It is therefore crucial to investigate 25 these differences and to adjust PSA protocols if necessary. Further, if PSA change is found to 26 be similar on average in men with and without prostate cancer then, for a future individual, 27 it may be possible to separate normal age-related change in PSA from pathologically 28 influenced changes which are a symptom of more aggressive cancer. 29 To this end, this article provides comparisons of (i) PSA change in men with and without 30 prostate cancer; (ii) PSA change in men with prostate cancer who were detected clinically or 31 through a PSA test; and (iii) PSA change in UK and US men in modern AS studies. 32 
Methods

33
Study Populations
34
Data were available from ongoing AS studies based at the Royal Marsden (15) 40 The Scandinavian Prostate Cancer study Group 4 (SPCG4) cohort analysed here contains 198 41 men and 2120 PSA tests (17) , and the University of Connecticut Health Centre (UCHC) cohort 42 consists of 101 men and 775 PSA test results (18, 19) . In both cohorts, men were diagnosed 43 with localised prostate cancer between 1989 and 1993 and represent a population whose 44 disease was likely detected at a later stage than in the PSA era, in the most part through 45 clinical presentation with symptoms, or incidentally during treatment for urological 46 conditions. 47 Two cohorts of men without prostate cancer were also included to examine differences in 48 PSA change between men with and without cancer. Data from the Baltimore Longitudinal Time from diagnosis, rather than age, was used as the time-varying covariate to allow for interpretation of the intercept as the average estimated PSA value at diagnosis. To correct 79 for different ages of men in the studies, we controlled for age at diagnosis in the models. 80 Within subject variation was allowed to be different in each study, to improve model fit, and 81 this is reported as a measure of the natural variation of PSA levels over time for men in each 82 cohort. Table 2 summarises the PSA data in each of the six cohorts. On average, the SPCG4 cohort 85 has the highest average PSA value at diagnosis (8.9ng/ml) while the UCHC cohort has the The left panel of Figure 1 shows a PSA curve for a hypothetical man in each cohort who has 100 a PSA value of 2ng/ml at age 50. This graph is used to show the similarities of the four 101 modern cohorts, whether they involve men with or without prostate cancer. However, the 102 results from the multilevel models suggest that men without cancer have much lower 103 average PSA values at age 50 -both have an average estimated PSA value below 1ng/ml. In disease status of men in these cohorts is unclear. The low average PSA value estimate at age 107 50 for the clinically detected men (SPCG4 and UCHC) is a result of extrapolating below the 108 ages of men in these two cohorts. In order to use PSA in AS, a model for "normal" PSA levels is needed, as a comparator for 158 observed PSA levels in men on AS. From Table 5 Table 5 it is evident that 201 differences in AS eligibility, monitoring and triggers to leave surveillance remain diverse. AS using PSA kinetics. Since the large US and Canadian studies drive the thresholds used to 218 make clinical decisions (e.g. PSA doubling time < 3 years used in a large Toronto study (38) 219 has been adopted by the largest ongoing AS study, PRIAS(39)), it is important to see 220 whether clinicians in the UK and Europe should base their PSA kinetic decisions on these 221 thresholds. We find little evidence for a difference in PSA change during follow-up between 222 US and UK men, which suggests that using thresholds from the large US and Canadian Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int. 2012. 
Results
10 ; PSAD<0.2ng/ml/cc every 3 mo. for 2 yrs, then every 6 mo. 
